PRAVASTATIN SODIUM tablet

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

PRAVASTATIN SODIUM (UNII: 3M8608UQ61) (PRAVASTATIN - UNII:KXO2KT9N0G)

可用日期:

Rising Health, LLC

INN（国际名称）:

PRAVASTATIN SODIUM

组成:

PRAVASTATIN SODIUM 10 mg

给药途径:

ORAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Pravastatin sodium tablets are indicated: - To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). - To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. - As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. - As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). - As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. - Primary dysbetalipoproteinemia. - Hypertriglyceridemia. - Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3) ]. - Hypersensitivity to a

產品總結:

Pravastatin sodium tablets, USP are supplied as: Pravastatin Sodium Tablets USP, 10 mg are yellow, rectangular shaped with rounded edges, biconvex, uncoated tablets debossed with ‘Y’ on one side and ‘37’ on the other side.                         Bottles of 90                   NDC 57237-164-90                         Bottles of 500                 NDC 57237-164-05                         Bottles of 1,000              NDC 57237-164-99 Pravastatin Sodium Tablets USP, 20 mg are white to off-white, rectangular shaped with rounded edges, biconvex, uncoated tablets debossed with ‘T’ on one side and ‘36’ on the other side.                           Bottles of 90                   NDC 57237-165-90                         Bottles of 500                 NDC 57237-165-05                         Bottles of 1,000              NDC 57237-165-99 Pravastatin Sodium Tablets USP, 40 mg are yellow, rectangular shaped with rounded edges, biconvex, uncoated tablets debossed with ‘Y’ on one side and ‘39’ on the other side.                         Bottles of 90                   NDC 57237-166-90                         Bottles of 500                 NDC 57237-166-05                         Bottles of 1,000              NDC 57237-166-99 Pravastatin Sodium Tablets USP, 80 mg are yellow, oval shaped biconvex, uncoated tablets, debossed with ‘Y’ on one side and ‘38’ on the other side.                         Bottles of 90               NDC 57237-167-90                         Bottles of 500             NDC 57237-167-05 Store at 20º to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.

授权状态:

Abbreviated New Drug Application

产品特点

PRAVASTATIN SODIUM - PRAVASTATIN SODIUM TABLET
RISING HEALTH, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
PRAVASTATIN SODIUM
TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
PRAVASTATIN SODIUM
TABLETS.
PRAVASTATIN SODIUM TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1991
RECENT MAJOR CHANGES
Contraindications, Pregnancy and Lactation Removed (4) 05/2022
Warnings and Precautions,
Immune-Mediated Necrotizing Myopathy Updated (5.2) 05/2022
INDICATIONS AND USAGE
Pravastatin sodium is an HMG-CoA reductase inhibitor (statin)
indicated (1):
To reduce the risk of myocardial infarction, myocardial
revascularization procedures, and cardiovascular
mortality in adults with elevated low-density lipoprotein cholesterol
(LDL-C) without clinically evident
coronary heart disease (CHD).
To reduce the risk of coronary death, myocardial infarction,
myocardial revascularization procedures,
stroke or transient ischemic attack, and slow the progression of
coronary atherosclerosis in adults with
clinically evident CHD.
As an adjunct to diet to reduce LDL-C in adults with primary
hyperlipidemia.
As an adjunct to diet to reduce LDL-C in pediatric patients ages 8
years and older with heterozygous
familial hypercholesterolemia (HeFH).
As an adjunct to diet for the treatment of adults with:
Primary dysbetalipoproteinemia.
Hypertriglyceridemia.
DOSAGE AND ADMINISTRATION
Take orally once daily at any time of the day, with or without food
(2.1).
For patients that require a high-intensity statin or are unable to
achieve their LDL-C goal receiving
pravastatin sodium tablets 80 mg daily, prescribe alternative
LDLC-lowering treatment (2.1).
Assess LDL-C when clinically appropriate, as early as 4 weeks after
initiating pravastatin sodium tablets,
and adjust the dosage if necessary (2.1).
Adults: recommended starting dosage is pravastatin sodium tablets 40
mg to 80 mg once daily. (2.2)
Pediatric Patients (2.3):
aged 8 to 13 years, the recommended dosage is 2